ITAbMed Ltd. is a clinical-stage biotech company located in Shanghai, China. The company was founded in 2020 and is located in Pudong, Shanghai, China. The company is a spin-off entity from the former “Generon BioMed Ltd.”.

ITAbMed continues the mission of “Innovating for Life” and focuses on the discovery and development of immunotherapy products to treat cancer. Although many breakthrough medications have been developed in the past decades, cancer remains a challenge for the medical community and society. Among the many therapies available to patients, we believe that immunotherapy is the key approach to fight against cancer with the potential for a cancer cure. Immunotherapies activate specific immune cells, such as T cells and NK cells, in patients to eliminate cancer cells. Immunotherapy treatments are proven to be able to cure many cancer patients, to extend patient survival, and to improve patient quality of life. The product we developed to eliminate cancerous B cells can also benefit patients with autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis.

Innovation and quality are the soul of iTAbMed Ltd.

Cancer immunotherapy: To kill and eliminate cancer by activating immune cells (such as T cells) against tumor cells, ultimately achieving clinical benefits for patients.